5005 ORAL Exploratory Subgroup Analysis of the TAMRAD Phase 2 GINECO Trial Comparing Tamoxifen (TAM) Plus Everolimus (RAD) With TAM Alone in Patients With Hormone-receptor-positive, HER2-negative Metastatic Breast Cancer (mBC) With Prior Exposure to Aromatase Inhibitors (Als): Implication for Research Strategies

Aromatase Inhibitors ◽

Subgroup Analysis ◽

Hormone Receptor ◽

Metastatic Breast ◽

Prior Exposure ◽

Phase 2 ◽

Research Strategies ◽

Hormone Receptor Positive

Abstract S1-6: TAMRAD: A GINECO Randomized Phase II Trial of Everolimus in Combination with Tamoxifen Versus Tamoxifen Alone in Patients (pts) with Hormone-Receptor Positive, HER2 Negative Metastatic Breast Cancer (MBC) with Prior Exposure to Aromatase Inhibitors (AI).

10.1158/0008-5472.sabcs10-s1-6 ◽

2010 ◽

Cited By ~ 18

Author(s):

T Bachelot ◽

C Bourgier ◽

C Cropet ◽

J-P Guastalla ◽

J-M Ferrero ◽

...

Keyword(s):

Breast Cancer ◽

Phase Ii ◽

Aromatase Inhibitors ◽

Hormone Receptor ◽

Phase Ii Trial ◽

Metastatic Breast ◽

Prior Exposure ◽

Randomized Phase Ii

Final results of the randomized phase 2 LEO trial and bone protective effects of everolimus for premenopausal hormone receptor‐positive, HER2 ‐negative metastatic breast cancer

International Journal of Cancer ◽

10.1002/ijc.33613 ◽

2021 ◽

Author(s):

Hyehyun Jeong ◽

Jae Ho Jeong ◽

Jeong Eun Kim ◽

Jin‐Hee Ahn ◽

Kyung Hae Jung ◽

...

Keyword(s):

Breast Cancer ◽

Hormone Receptor ◽

Metastatic Breast ◽

Protective Effects ◽

Phase 2 ◽

Randomized Phase 2

Abstract P1-19-08: Neratinib + trastuzumab + fulvestrant for HER2-mutant, hormone receptor-positive, metastatic breast cancer: Updated results from the phase 2 SUMMIT ‘basket’ trial

10.1158/1538-7445.sabcs19-p1-19-08 ◽

2020 ◽

Author(s):

Hans Wildiers ◽

Valentina Boni ◽

Cristina Saura ◽

Mafalda Oliveira ◽

Komal Jhaveri ◽

...

Keyword(s):

Breast Cancer ◽

Hormone Receptor ◽

Metastatic Breast ◽

Phase 2 ◽

Basket Trial

The prognostic significance of single hormone receptor positive metastatic breast cancer: An analysis of three randomised phase III trials of aromatase inhibitors

The Breast ◽

10.1016/j.breast.2009.09.002 ◽

2009 ◽

Vol 18 (6) ◽

pp. 351-355 ◽

Cited By ~ 13

Author(s):

R. Stuart-Harris ◽

B. Shadbolt ◽

C. Palmqvist ◽

H.A. Chaudri Ross

Keyword(s):

Breast Cancer ◽

Aromatase Inhibitors ◽

Hormone Receptor ◽

Prognostic Significance ◽

Metastatic Breast ◽

Phase Iii ◽

Phase Iii Trials

Abstract LB-177: First-line bevacizumab (BEV) + chemotherapy for hormone receptor-positive metastatic breast cancer (mBC): Subgroup analysis of the open-label non-inferiority TURANDOT phase III trial.

10.1158/1538-7445.am2013-lb-177 ◽

2013 ◽

Author(s):

Zsuzsanna Kahán ◽

Lubos Petruzelka ◽

Alexandru Eniu ◽

Rodica Anghel ◽

Krassimir Koynov ◽

...

Keyword(s):

Breast Cancer ◽

Subgroup Analysis ◽

Hormone Receptor ◽

Metastatic Breast ◽

Phase Iii ◽

First Line ◽

Open Label ◽

Phase Iii Trial ◽

Hormone Receptor Positive

Prevention of everolimus-related stomatitis in women with hormone receptor-positive, HER2-negative metastatic breast cancer using dexamethasone mouthwash (SWISH): a single-arm, phase 2 trial

The Lancet Oncology ◽

10.1016/s1470-2045(17)30109-2 ◽

2017 ◽

Vol 18 (5) ◽

pp. 654-662 ◽

Cited By ~ 88

Author(s):

Hope S Rugo ◽

Lasika Seneviratne ◽

J Thaddeus Beck ◽

John A Glaspy ◽

Julio A Peguero ◽

...

Keyword(s):

Breast Cancer ◽

Hormone Receptor ◽

Metastatic Breast ◽

Phase 2 ◽

Phase 2 Trial ◽

Hormone Receptor Positive

Abstract PD1-05: Latest findings from the breast cancer cohort in SUMMIT - a phase 2 ‘basket’ trial of neratinib + trastuzumab + fulvestrant forHER2-mutant, hormone receptor-positive, metastatic breast cancer

10.1158/1538-7445.sabcs20-pd1-05 ◽

2021 ◽

Author(s):

Komal Jhaveri ◽

Cristina Saura ◽

Angel Guerrero-Zotano ◽

Iben Spanggaard ◽

François-Clement Bidard ◽

...

Keyword(s):

Breast Cancer ◽

Hormone Receptor ◽

Metastatic Breast ◽

Phase 2 ◽

Breast Cancer Cohort ◽

Basket Trial

1850 Safety of everolimus plus exemestane in elderly patients with Hormone-Receptor-Positive (HR+), HER2- locally advanced or metastatic breast cancer progressing on prior non-steroidal aromatase inhibitors (NSAIs): BALLET (CRAD001YIC04)

European Journal of Cancer ◽

10.1016/s0959-8049(16)30800-0 ◽

2015 ◽

Vol 51 ◽

pp. S282

Author(s):

P. Neven ◽

D. Generali ◽

E.M. Ciruelos ◽

I. Lang ◽

J.G. Gavila ◽

...

Keyword(s):

Breast Cancer ◽

Elderly Patients ◽

Aromatase Inhibitors ◽

Hormone Receptor ◽

Locally Advanced ◽

Metastatic Breast ◽

Steroidal Aromatase Inhibitors

Randomized phase II trial of fulvestrant alone or in combination with bortezomib in hormone receptor-positive metastatic breast cancer resistant to aromatase inhibitors: a New York Cancer Consortium trial

npj Breast Cancer ◽

10.1038/npjbcancer.2016.37 ◽

2016 ◽

Vol 2 (1) ◽

Cited By ~ 10

Author(s):

Kerin Adelson ◽

Bhuvaneswari Ramaswamy ◽

Joseph A Sparano ◽

Paul J Christos ◽

John J Wright ◽

...

Keyword(s):

Breast Cancer ◽

New York ◽

Phase Ii ◽

Aromatase Inhibitors ◽

Hormone Receptor ◽

Phase Ii Trial ◽

Metastatic Breast ◽

Randomized Phase Ii

The prognostic significance of single hormone receptor positive metastatic breast cancer: An analysis of three randomised phase III trials of aromatase inhibitors

The Breast ◽

10.1016/j.breast.2010.01.013 ◽

2010 ◽

Vol 19 (2) ◽

pp. 149

Keyword(s):

Breast Cancer ◽

Aromatase Inhibitors ◽

Hormone Receptor ◽

Prognostic Significance ◽

Metastatic Breast ◽

Phase Iii ◽

Phase Iii Trials